Jean-Pierre Van geertruyden
Quick facts
Phase 3 pipeline
- AV2 · Diabetes
AV2 is a small molecule that targets the SGLT2 receptor. - MVA-BN half-dose regimen · Immunology / Infectious Disease
MVA-BN is a modified vaccinia Ankara-based vaccine expressing monkeypox antigens that primes the immune system to recognize and respond to monkeypox virus infection. - MVA-BN standard regimen · Immunology / Infectious Disease
MVA-BN is a live attenuated vaccinia virus-based vaccine that stimulates immune responses against monkeypox virus antigens.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: